Focused on developing a vibrant biomedical sciences research ecosystem, Singapore has built up a strong scientific foundation with seven research institutes and five research consortia in key fields that include clinical sciences, genomics, bioengineering, molecular/cell biology, medical biology, bio-imaging and immunology. More than 50 companies are carrying out biomedical sciences R&D that includes drug discovery, translational and clinical research, frequently collaborating with these research institutes.
The city-state has also made significant progress in translational and clinical research. It has built up key infrastructure such as the Investigational Medicine Units dedicated for early-phase trials in public hospitals, as well as the Singapore Clinical Research Institute, which focuses on supporting later-stage trials. These facilities will in turn support the growing community of clinician scientists in Singapore.
In the years ahead, as Singapore builds on its foundation in good science and capabilities in translational and clinical research, the city-state is well positioned to support the industry in its efforts to accelerate the drug discovery process with next-generation technologies, while focusing on key diseases such as cancer, metabolic diseases, neurological diseases, infectious diseases and eye diseases.
Singapore’s integrated research ecosystem enables companies to access multidisciplinary capabilities in a single location, which improves R&D decision-making and accelerates drug discovery and development. More than 30 of the world’s leading biomedical sciences companies (including GlaxoSmithKline, Novartis and Takeda) are leveraging Singapore as a key home base to drive innovation.
The multi-ethnic city-state which is the leading logistics hub globally and has world class intellectual property protection, is now Asia’s fastest-growing bio-cluster, presenting strategic partnership opportunities with research institutes, corporate labs and public hospitals to develop new medicines and future therapies that can be customised for regional and global markets.
Singapore is reputed for its clinical research and clinical trials management activities in Asia. As the secretariat for the APEC Coordinating Centre for Good Clinical Practice (GCP), Singapore plays a strategic role in developing GCP in Asia, steering initiatives such as the training of clinical research personnel and developing a conducive environment for multi-site clinical trials in the region.